EFFECT OF IT KETOROLAC FOLLOWING ACUTE OPIOID EXPOSURE

急性阿片类药物暴露后酮咯酸的影响

• 批准号: 7951400
• 负责人: James Eisenach
• 金额: $ 1.22万
• 依托单位: WAKE FOREST UNIVERSITY HEALTH SCIENCES
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-03-01 至 2010-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7951400
• 关键词: Acute; Area; Capsaicin; Clinical Research; Computer Retrieval of Information on Scientific Projects Database; Dinoprostone; Funding; Grant; Heating; Hyperalgesia; Hypersensitivity; Infusion procedures; Institution; Ketorolac; Mechanics; Opioid; Outcome Measure; Randomized; Research; Research Personnel; Resources; Saline; Source; Spinal; United States National Institutes of Health; allodynia; healthy volunteer; primary outcome; remifentanil; secondary outcome

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Hypothesis: IV remifentanil stimulates spinal COX activity, leading to increased CSF PGE2 concentrations and areas of capsaicin-induced mechanical hypersensitivity after remifentanil infusion, and these effects will be blocked by intrathecal ketorolac Synopsis: Areas of mechanical hyperalgesia and allodynia will be established by topical capsaicin + intermittent heat in healthy volunteers, who will be randomized to receive intrathecal saline or ketorolac during remifentanil infusion, with primary outcome measure area of hyperalgesia and secondary outcome measure CSF PGE2 concentration after stopping remifentanil.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目和 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 假设：静脉注射瑞芬太尼会刺激脊髓 COX 活性，导致脑脊液 PGE2 浓度增加以及瑞芬太尼输注后辣椒素诱导的机械过敏区域增加，而鞘内注射酮咯酸会阻断这些作用 概要：将通过健康志愿者的局部辣椒素+间歇性热建立机械性痛觉过敏和异常性疼痛的区域，这些志愿者将在瑞芬太尼输注期间随机接受鞘内盐水或酮咯酸，主要结果测量痛觉过敏区域，次要结果测量CSF PGE2浓度。停止瑞芬太尼。